LIGACEM BioScience Unveils LCB 2.0 R&D Strategy Targeting ADC Innovation and Next‑Gen Modalities

LIGACEM BioScience (리 가 켐 바이오 사이언스) disclosed its new “LCB 2.0” research and development strategy during the Global R&D Day 2026 held on June 8. The company said the plan is designed to strengthen its global new‑drug development capabilities, secure post‑ADC (antibody‑drug conjugate) next‑generation modalities, and accelerate high‑value technology transfer focused on late‑stage clinical entry. Three research heads outlined the roadmap, emphasizing innovation of existing platforms, expansion into new modalities, and integration of artificial intelligence and collaborative research to maintain a technological edge. LIGACEM BioScience’s vision includes acquiring ultra‑competitive global technologies, moving candidates into late‑phase clinical trials, and speeding up licensing or out‑licensing of next‑generation platform assets.